PEDRO
PÉREZ SEGURA
Profesor asociado de Ciencias de la Salud
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicacions en col·laboració amb investigadors/es de Hospital de la Santa Creu i Sant Pau (20)
2024
-
A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma
Journal of Neuro-Oncology, Vol. 166, Núm. 3, pp. 407-415
-
Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma (Journal of Neuro-Oncology, (2024), 166, 3, (407-415), 10.1007/s11060-023-04513-1)
Journal of Neuro-Oncology
2021
-
Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology)
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 799-811
2020
-
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
Neuro-oncology, Vol. 22, Núm. 12, pp. 1851-1861
2018
-
Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1529-1537
2017
-
FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence
Clinical and Translational Oncology, Vol. 19, Núm. 8, pp. 997-1009
2016
-
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
Journal of Neuro-Oncology, Vol. 127, Núm. 3, pp. 569-579
2015
-
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
Clinical and Translational Oncology, Vol. 17, Núm. 9, pp. 743-750
-
Mammographic density and breast cancer in women from high risk families
Breast Cancer Research, Vol. 17, Núm. 1
2014
-
Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC)
Clinical and Translational Oncology, Vol. 16, Núm. 3, pp. 280-284
-
Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry
Journal of Neuro-Oncology, Vol. 116, Núm. 2, pp. 413-419
-
Erratum: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry [J Neurooncol, 116, (2014), 413-419, DOI 10.1007/s11060-013-1316-y]
Journal of Neuro-Oncology
2013
2012
-
Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer
Breast Cancer Research and Treatment, Vol. 132, Núm. 1, pp. 307-315
-
Hereditary pancreatic cancer: Molecular bases and their application in diagnosis and clinical management. A guideline of the TTD group
Clinical and Translational Oncology, Vol. 14, Núm. 8, pp. 553-563
-
SEOM guideline for the treatment of malignant glioma
Clinical and Translational Oncology, Vol. 14, Núm. 7, pp. 545-550
2011
-
Evidence for a link between TNFRSF11A and risk of breast cancer
Breast Cancer Research and Treatment, Vol. 129, Núm. 3, pp. 947-954
2010
-
Extended-schedule dose-dense temozolomide in refractory gliomas
Journal of Neuro-Oncology, Vol. 96, Núm. 3, pp. 417-422
2009
-
Spanish society of medical oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients
Clinical and Translational Oncology, Vol. 11, Núm. 7, pp. 446-454
2003
-
Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics
Journal of Medical Genetics, Vol. 40, Núm. 7, pp. 503-510